1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Wang L, Xiong Y, Sun Y, Fang Z, Li L, Ji H
and Shi T: HLungDB: An integrated database of human lung cancer
research. Nucleic Acids Res. 38(Database Issue): D665–D669. 2010.
View Article : Google Scholar :
|
3
|
Inamura K and Ishikawa Y: Lung cancer
progression and metastasis from the prognostic point of view. Clin
Exp Metastasis. 27:389–397. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Mihaljevic AL, Michalski CW, Friess H and
Kleeff J: Molecular mechanism of pancreatic cancer - understanding
proliferation, invasion, and metastasis. Langenbecks Arch Surg.
395:295–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
5
|
Hoon DS, Ferris R, Tanaka R, Chong KK,
Alix-Panabières C and Pantel K: Molecular mechanisms of metastasis.
J Surg Oncol. 103:508–517. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
van der Geer P, Hunter T and Lindberg RA:
Receptor protein-tyrosine kinases and their signal transduction
pathways. Annu Rev Cell Biol. 10:251–337. 1994. View Article : Google Scholar : PubMed/NCBI
|
7
|
Pasquale EB: Eph receptors and ephrins in
cancer: Bidirectional signalling and beyond. Nat Rev Cancer.
10:165–180. 2010. View
Article : Google Scholar : PubMed/NCBI
|
8
|
Matsumura Y, Umemura S, Ishii G, Tsuta K,
Matsumoto S, Aokage K, Hishida T, Yoshida J, Ohe Y, Suzuki H, et
al: Expression profiling of receptor tyrosine kinases in high-grade
neuroendocrine carcinoma of the lung: A comparative analysis with
adenocarcinoma and squamous cell carcinoma. J Cancer Res Clin
Oncol. 141:2159–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Eph Nomenclature Committee: Unified
nomenclature for Eph family receptors and their ligands, the
ephrins. Cell. 90:403–404. 1997. View Article : Google Scholar
|
10
|
Kiyokawa E, Takai S, Tanaka M, Iwase T,
Suzuki M, Xiang YY, Naito Y, Yamada K, Sugimura H and Kino I:
Overexpression of ERK, an EPH family receptor protein tyrosine
kinase, in various human tumors. Cancer Res. 54:3645–3650.
1994.PubMed/NCBI
|
11
|
Tang XX, Zhao H, Robinson ME, Cohen B,
Cnaan A, London W, Cohn SL, Cheung NK, Brodeur GM, Evans AE and
Ikegaki N: Implications of EPHB6, EFNB2, and EFNB3 expressions in
human neuroblastoma. Proc Natl Acad Sci USA. 97:10936–10941. 2000.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Walker-Daniels J, Coffman K, Azimi M, Rhim
JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ and Kinch MS:
Overexpression of the EphA2 tyrosine kinase in prostate cancer.
Prostate. 41:275–280. 1999. View Article : Google Scholar : PubMed/NCBI
|
13
|
Taneja R, Thisse B, Rijli FM, Thisse C,
Bouillet P, Dollé P and Chambon P: The expression pattern of the
mouse receptor tyrosine kinase gene MDK1 is conserved through
evolution and requires Hoxa-2 for rhombomere-specific expression in
mouse embryos. Dev Biol. 177:397–412. 1996. View Article : Google Scholar : PubMed/NCBI
|
14
|
Hafner C, Schmitz G, Meyer S, Bataille F,
Hau P, Langmann T, Dietmaier W, Landthaler M and Vogt T:
Differential gene expression of Eph receptors and ephrins in benign
human tissues and cancers. Clin Chem. 50:490–499. 2004. View Article : Google Scholar : PubMed/NCBI
|
15
|
Surawska H, Ma PC and Salgia R: The role
of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev.
15:419–433. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Nakanishi H, Nakamura T, Canaani E and
Croce CM: ALL1 fusion proteins induce deregulation of EphA7 and ERK
phos-phorylation in human acute leukemias. Proc Natl Acad Sci USA.
104:14442–14447. 2007. View Article : Google Scholar
|
17
|
Wu Z, Liu K, Wang Y, Xu Z, Meng J and Gu
S: Upregulation of microRNA-96 and its oncogenic functions by
targeting CDKN1A in bladder cancer. Cancer Cell Int. 15:1072015.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Suen DF, Norris KL and Youle RJ:
Mitochondrial dynamics and apoptosis. Genes Dev. 22:1577–1590.
2008. View Article : Google Scholar : PubMed/NCBI
|
19
|
Slee EA, Adrain C and Martin SJ:
Executioner caspase-3, -6, and -7 perform distinct, non-redundant
roles during the demolition phase of apoptosis. J Biol Chem.
276:7320–7326. 2001. View Article : Google Scholar
|
20
|
Liu S, Cheng L, Bi X, Zhang X, Liu S, Bai
X, Li F and Zhao AZ: Elevation of ω-3 polyunsaturated fatty acids
attenuates PTEN-deficiency induced endometrial cancer development
through regulation of COX-2 and PGE2 production. Sci Rep.
5:14958
|
21
|
Kinch MS, Moore MB and Harpole DH Jr:
Predictive value of the EphA2 receptor tyrosine kinase in lung
cancer recurrence and survival. Clin Cancer Res. 9:613–618.
2003.PubMed/NCBI
|
22
|
Kataoka H, Igarashi H, Kanamori M, Ihara
M, Wang JD, Wang YJ, Li ZY, Shimamura T, Kobayashi T, Maruyama K,
et al: Correlation of EPHA2 overexpression with high microvessel
count in human primary colorectal cancer. Cancer Sci. 95:136–141.
2004. View Article : Google Scholar : PubMed/NCBI
|
23
|
Nakamura R, Kataoka H, Sato N, Kanamori M,
Ihara M, Igarashi H, Ravshanov S, Wang YJ, Li ZY, Shimamura T, et
al: EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci.
96:42–47. 2005. View Article : Google Scholar : PubMed/NCBI
|
24
|
Martinou JC and Green DR: Breaking the
mitochondrial barrier. Nat Rev Mol Cell Biol. 2:63–67. 2001.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Arnoult D, Gaume B, Karbowski M, Sharpe
JC, Cecconi F and Youle RJ: Mitochondrial release of AIF and EndoG
requires caspase activation downstream of Bax/Bak-mediated
permeabilization. EMBO J. 22:4385–4399. 2003. View Article : Google Scholar : PubMed/NCBI
|